Physician Assistant, Medical · Williamsville, NY
NPI
1700808920
Since 2006
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
295 Essjay Rd
Williamsville, NY, 14221
Phone (166) 301-1007
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
411 services
Medicare patients, 2024
207
Average age 73
Drug cost, 2024
$2.7M
5,483 prescriptions
Company payments, 2025
$2,510
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jennifer Rankie was code 99214 (office e&m - established), 189 times for 146 patients. In total Jennifer Rankie billed 411 services in 8 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-09-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 189 | 146 | $73.63 | $14K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 94 | 77 | $10.28 | $966 |
| 99204 Office E&M - New | Office | 62 | 62 | $95.72 | $5,935 |
| 99213 Office E&M - Established | Office | 56 | 50 | $50.47 | $2,826 |
By year: 2022 $18K for 274 services; 2023 $22K for 310 services; 2024 $24K for 411 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jennifer Rankie prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 1,011 prescriptions and refills. In total Jennifer Rankie wrote 5,483 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 1,011 | 1,249 | 454 | $40K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 803 | 1,531 | 287 | $943K |
| Prednisone Generic | 483 | 542 | 304 | $2,120 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 320 | 644 | 125 | $90K |
| Breo Ellipta Fluticasone/Vilanterol | 288 | 562 | 99 | $215K |
| Azithromycin Generic | 281 | 314 | 177 | $2,286 |
| Montelukast Sodium Generic | 228 | 545 | 74 | $3,573 |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 221 | 324 | 68 | $148K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 215 | 439 | 87 | $267K |
| Spiriva Respimat Tiotropium Bromide | 131 | 229 | 42 | $114K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 110 | 200 | 38 | $88K |
| Fluticasone Propionate Generic | 109 | 178 | 49 | $1,847 |
| Qvar Redihaler Beclomethasone Dipropionate | 105 | 157 | 33 | $38K |
| Ventolin Hfa Albuterol Sulfate | 90 | 120 | 28 | $8,370 |
| Symbicort Budesonide/Formoterol Fumarate | 88 | 194 | 37 | $43K |
Brand drugs: 3,181 claims; generic drugs: 2,302 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jennifer Rankie $2,510 ($2,510 in general payments such as food, travel and fees) from 14 companies. The largest payer was Genzyme Corporation with $554.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 16 | $554 |
| GlaxoSmithKline, LLC. GSK | 28 | $502 |
| Regeneron Healthcare Solutions, Inc. REGN | 12 | $355 |
| AstraZeneca Pharmaceuticals LP AZN | 15 | $343 |
| Grifols USA, LLC | 11 | $211 |
| Viatris Specialty LLC | 10 | $144 |
| Regeneron Pharmaceuticals, Inc. REGN | 1 | $126 |
| Verona Pharma, Inc. VRNA | 3 | $70.77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $67.34 |
| Electromed, Inc. ELMD | 2 | $42.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.